• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声引导下射频消融治疗甲状腺微小乳头状癌中基质金属蛋白酶-2 和 -9 的临床价值。

Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma.

机构信息

Department of Ultrasound, Beilun People's Hospital of Ningbo, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, Zhejiang, China.

出版信息

J Int Med Res. 2020 Aug;48(8):300060520917581. doi: 10.1177/0300060520917581.

DOI:10.1177/0300060520917581
PMID:32772889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7418228/
Abstract

OBJECTIVE

This study aimed to investigate serum matrix metalloproteinase (MMP)-2 and MMP-9 levels in patients with papillary thyroid carcinoma (PTC).

METHODS

Forty-one patients with PTC undergoing ultrasound-guided radiofrequency ablation (RFA) and 56 controls were included. Serum MMP-2 and MMP-9 levels were determined by enzyme-linked immunosorbent assay before and after surgery. Potential affecting factors were evaluated by logistic regression analysis.

RESULTS

Serum MMP-2 and MMP-9 levels were significantly higher in PTC patients compared with controls, and decreased significantly after surgery. According to receiver operating characteristic curve analysis, diagnostic values for preoperative serum MMP-2 and MMP-9 levels were 82.4% and 86.6%. There was no contrast-agent perfusion in the ablation zone in 88.5% of lesions, and enhancement within or at the lesion edge in 11.4%. The volume reduction at 3 months' follow-up was >40%. Age, microcalcification, irregular shape, and lesion diameter and number were influencing factors for PTC. Age, and lesion diameter and number were independent risk factors, while calcification and morphology were protective factors.

CONCLUSION

Serum MMP-2 and MMP-9 levels have important clinical values for the diagnosis and treatment of PTC by RFA. Preoperative serum MMP-2 and MMP-9 levels, combined with other affecting factors, contribute to disease prognosis.

摘要

目的

本研究旨在探讨甲状腺乳头状癌(PTC)患者血清基质金属蛋白酶(MMP)-2 和 MMP-9 水平。

方法

纳入 41 例行超声引导下射频消融(RFA)的 PTC 患者和 56 例对照者。采用酶联免疫吸附试验检测患者术前及术后血清 MMP-2 和 MMP-9 水平,采用 logistic 回归分析评估潜在影响因素。

结果

与对照者相比,PTC 患者血清 MMP-2 和 MMP-9 水平显著升高,术后显著下降。根据受试者工作特征曲线分析,术前血清 MMP-2 和 MMP-9 水平对 PTC 的诊断价值分别为 82.4%和 86.6%。88.5%病灶消融区无造影剂灌注,11.4%呈病灶内或边缘强化。3 个月随访时,体积缩小率>40%。年龄、微钙化、不规则形状、病灶直径和数量是 PTC 的影响因素。年龄、病灶直径和数量是独立危险因素,而钙化和形态是保护因素。

结论

血清 MMP-2 和 MMP-9 水平对 RFA 治疗 PTC 的诊断具有重要的临床价值。术前血清 MMP-2 和 MMP-9 水平与其他影响因素相结合,有助于预测疾病预后。

相似文献

1
Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma.超声引导下射频消融治疗甲状腺微小乳头状癌中基质金属蛋白酶-2 和 -9 的临床价值。
J Int Med Res. 2020 Aug;48(8):300060520917581. doi: 10.1177/0300060520917581.
2
[Effect of Calcification on the Ultrasound-Guided Radiofrequency Ablation of Papillary Thyroid Carcinoma].[钙化对超声引导下甲状腺乳头状癌射频消融的影响]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Oct;45(5):803-808. doi: 10.3881/j.issn.1000-503X.15504.
3
Ultrasonography-guided radiofrequency ablation vs. surgery for the treatment of solitary T1bN0M0 papillary thyroid carcinoma: A comparative study.超声引导下射频消融与手术治疗单发 T1bN0M0 期甲状腺乳头状癌的对比研究。
Clin Endocrinol (Oxf). 2021 Apr;94(4):684-691. doi: 10.1111/cen.14361. Epub 2020 Dec 9.
4
Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study.超声引导下射频消融治疗 T2N0M0 期甲状腺乳头状癌的初步研究。
Int J Hyperthermia. 2021;38(1):402-408. doi: 10.1080/02656736.2021.1895332.
5
Clinical outcomes of ultrasound-guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow-up.超声引导下射频消融治疗单发 T1N0M0 期甲状腺乳头状癌的临床疗效:一项超过 5 年随访的回顾性研究。
Cancer. 2023 Aug 15;129(16):2469-2478. doi: 10.1002/cncr.34802. Epub 2023 Apr 15.
6
Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study.射频消融治疗后甲状腺乳头状癌的超声演变及病理结果:一项为期五年的回顾性队列研究。
Thyroid. 2024 Jan;34(1):54-63. doi: 10.1089/thy.2023.0415. Epub 2023 Nov 20.
7
Surgery After Ultrasound-Guided Radiofrequency Ablation for Papillary Thyroid Carcinoma in 21 Patients: A Retrospective Study from a Single Center in China.21例甲状腺乳头状癌超声引导下射频消融术后手术:来自中国单中心的回顾性研究
Med Sci Monit. 2020 Nov 22;26:e928391. doi: 10.12659/MSM.928391.
8
Long-term results of radiofrequency ablation for locally recurrent papillary thyroid carcinoma.射频消融治疗局部复发性甲状腺乳头状癌的长期疗效。
Int J Hyperthermia. 2023;40(1):2191912. doi: 10.1080/02656736.2023.2191912.
9
Comparison of ultrasound-guided radiofrequency ablation versus thyroid lobectomy for T1bN0M0 papillary thyroid carcinoma.超声引导下射频消融与甲状腺叶切除术治疗 T1bN0M0 期甲状腺乳头状癌的比较。
Eur Radiol. 2023 Jan;33(1):730-740. doi: 10.1007/s00330-022-08963-5. Epub 2022 Jul 27.
10
Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.射频消融治疗局部复发性甲状腺乳头状癌的长期疗效。
Eur Radiol. 2019 Sep;29(9):4897-4903. doi: 10.1007/s00330-019-06063-5. Epub 2019 Feb 25.

引用本文的文献

1
Matrix Metalloproteinase 9/microRNA-145 Ratio: Bridging Genomic and Immunological Variabilities in Thyroid Cancer.基质金属蛋白酶9/微小RNA - 145比值:连接甲状腺癌中的基因组和免疫变异性
Biomedicines. 2023 Nov 1;11(11):2953. doi: 10.3390/biomedicines11112953.
2
Anti-metastatic effect of taraxasterol on prostate cancer cell lines.蒲公英甾醇对前列腺癌细胞系的抗转移作用。
Res Pharm Sci. 2023 Jun 1;18(4):439-448. doi: 10.4103/1735-5362.378090. eCollection 2023 Jul-Aug.
3
Clinical significance of matrix metalloproteinase-9 expression in papillary thyroid carcinoma: a meta-analysis.

本文引用的文献

1
Identifying predictive factors for efficacy in high intensity focused ultrasound (HIFU) ablation of benign thyroid nodules - a retrospective analysis.识别高强度聚焦超声(HIFU)消融良性甲状腺结节疗效的预测因素 - 回顾性分析。
Int J Hyperthermia. 2020;37(1):324-331. doi: 10.1080/02656736.2020.1747646.
2
Ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma: a retrospective analysis of 198 patients.超声引导下射频消融治疗甲状腺微小乳头状癌:198 例回顾性分析。
Int J Hyperthermia. 2020;37(1):168-174. doi: 10.1080/02656736.2019.1708480.
3
MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma.
基质金属蛋白酶-9 在甲状腺乳头状癌中的表达的临床意义:一项荟萃分析。
World J Surg Oncol. 2023 Jul 26;21(1):225. doi: 10.1186/s12957-023-03101-x.
4
The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.MMP-9 及其抑制剂在不同类型甲状腺癌中的作用。
Molecules. 2023 Apr 25;28(9):3705. doi: 10.3390/molecules28093705.
5
Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer.基质金属蛋白酶及其抑制剂在局部侵袭性甲状腺乳头状癌中的作用
Biomedicines. 2022 Dec 8;10(12):3178. doi: 10.3390/biomedicines10123178.
6
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.我们能否预测分化型甲状腺癌的行为?遗传和分子标志物的作用。
Medicina (Kaunas). 2021 Oct 19;57(10):1131. doi: 10.3390/medicina57101131.
分化型甲状腺癌患者外周血中的基质金属蛋白酶-2、基质金属蛋白酶-9、金属蛋白酶组织抑制因子-1和金属蛋白酶组织抑制因子-2
Cancer Manag Res. 2019 Dec 23;11:10675-10681. doi: 10.2147/CMAR.S233776. eCollection 2019.
4
Role of adjuvant therapy with radioactive iodine in patients with elevated serum thyroglobulin after neck reoperation due to recurrent papillary thyroid cancer: a monoinstitutional comparative study.放射性碘辅助治疗在因复发性乳头状甲状腺癌行颈部再次手术后血清甲状腺球蛋白升高患者中的作用:一项单机构比较研究。
Endocrine. 2020 Apr;68(1):144-150. doi: 10.1007/s12020-019-02165-8. Epub 2019 Dec 21.
5
Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer.基质金属蛋白酶及其抑制剂在甲状腺乳头状癌颈淋巴结转移中的作用。
Clin Otolaryngol. 2020 Jan;45(1):55-62. doi: 10.1111/coa.13466. Epub 2019 Nov 13.
6
Effect of chronic lymphocytic thyroiditis on the efficacy and safety of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma.慢性淋巴细胞性甲状腺炎对超声引导下射频消融治疗甲状腺微小乳头状癌疗效及安全性的影响。
Cancer Med. 2019 Sep;8(12):5450-5458. doi: 10.1002/cam4.2406. Epub 2019 Jul 30.
7
Radiofrequency Ablation for Benign Thyroid Nodules: 1-Year Follow-Up in 184 Patients.射频消融治疗良性甲状腺结节:184 例患者 1 年随访结果。
World J Surg. 2019 Oct;43(10):2447-2453. doi: 10.1007/s00268-019-05044-5.
8
[Central compartment reoperation for recurrent/persistent differentiated thyroid cancer].[复发性/持续性分化型甲状腺癌的中央区再次手术]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Apr 7;52(4):263-266. doi: 10.3760/cma.j.issn.1673-0860.2017.04.005.
9
Factors associated with initial incomplete ablation for benign thyroid nodules after radiofrequency ablation: First results of CEUS evaluation.射频消融术后良性甲状腺结节首次消融不完全的相关因素:超声造影评估的初步结果
Clin Hemorheol Microcirc. 2017;65(4):393-405. doi: 10.3233/CH-16208.
10
[Ultrasound guided percutaneous microwave ablation in the treatment of recurrent thyroid nodules].超声引导下经皮微波消融治疗复发性甲状腺结节
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Apr;29(7):622-4.